An interventional study of Screening by low-dose CT scan in Lung Cancer, sponsored by Odense University Hospital. Active, not recruiting at 2 sites in Denmark. Open to participants aged 60 Years to 74 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-15.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Lung Neoplasms with a site in Denmark — 35 open to participants now, 47 under way, 8 of them phase 3. Lung Neoplasms · Denmark.
Among the 124 studies in Lung Neoplasms with a site in Denmark, this one is the 5th largest by enrollment of the 94 interventional ones that give a count, is one of 11 that started in 2024, is one of 46 with no phase, reaches primary completion later than 17 of the 46 other live ones, and was the 100th registered.
5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.
Browse Lung Neoplasms studies →35 of the 124 studies in Lung Neoplasms with a site in Denmark are open now. Recruiting first, the newest first:
Aarhus University Hospital · Sites in Denmark
Ages 18+
Vejle Hospital · Sites in Denmark
Ages 50+
Vejle Hospital · Sites in Denmark
Ages 50+
Ditte Krag-Hansen · Sites in Denmark
Ages 18+
Zealand University Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.
This study: 60 Years to 74 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 1998; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,332 is above the median of 60 across 3,668 interventional studies indexed under Lung Neoplasms.
Median enrollment 158 across the 94 interventional studies, 105 across the 30 observational. Of the 60 that completed or were terminated, 12 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 124 have an industry lead sponsor. The 10 most frequent:
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
Odense University Hospital has 7 studies filed under Lung Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Lung Neoplasms with a site in Denmark that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05920356Phase 3AmgenA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | 2027-06-30 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
| NCT06537804Odense University HospitalProject Lung Cancer Screening in Southern Denmark | 2026-12-31 |
| NCT05053997Zealand University HospitalNavigate - Improving Survival and Quality of Life in Vulnerable Lung Cancer Patients | 2026-12-31 |
| NCT04699188Novartis PharmaceuticalsStudy of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | 2027-01-25 |
Add all 12 to your calendar (.ics) → With an account.
Among the 124 studies in Lung Neoplasms with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
One thousand randomly selected voluntary citizens aged 60-74 years old, who are heavy current or former smokers with an increased risk of developing lung cancer may be included in the project. The participants will be identified through an initial questionnaire survey concerning smoking history and general health. Project participants are offered a low-dose CT (LDCT) scan annually for three consecutive years. In relation to the first scan, a lung function test will also be performed. The screening process will be evaluated for possible national implementation of a lung cancer screening program in Denmark.
This pilot study is a prospective interventional feasibility study. The primary goal is to evaluate the impact on healthcare organization, administration of resources and costs, and thereby assessing the feasibility of implementing systematic screening for lung cancer among people at high risk in Denmark (current or former heavy smokers). The pilot study will be performed on Funen in the Region of Southern Denmark and will run over three years (2024-2026). One thousand randomly selected participants aged 60-74 years old, who meet the screening criteria, will receive annual LDCT scans for three consecutive years.
Data will be collected continuously throughout the study period. The analysis method will focus on descriptive statistics to display questionnaire response and participation rates, and assess the impact of screening on healthcare organization and resources. Furthermore, the result including direct and indirect effects of the screening process (e.g. number of positive findings, false positive results, and follow-up rates). The analyses will also include healthcare economics including resource consumption as well as qualitative assessments to describe potential differences between the screening population versus a corresponding control group of heavy smokers. Finally, the radiologists' assessments of the project's LDCT scans are compared to the assessment of an artificially intelligent algorithm to explore the opportunities of supporting a future national screening program.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Low-dose CT scans are performed once a year from 2024 to 2026 to screen for lung cancer including a lung function test the first year of attendance (2024).
Radiation: Screening by low-dose CT scan
Citizens from the cohort who are randomized to no intervention.
Screening for lung cancer by low-dose CT scan
Lung cancer screening cost-effectiveness analysis quantified in the form of incremental cost-effectiveness ratio threshold
ratio
Time frame: Up to 36 months
Characteristics of citizens from the cohort based on registry data
Registry data
Time frame: Up to 36 months
Participation rate
Number and percentage of citizens completing the screening trial
Time frame: 36 months (complete study period)
Dropouts
Number and percentage of citizens included that dropout during the study period
Time frame: 36 months (complete study period)
Lung cancer found on low dose CT-scans
Number and percentage
Time frame: Baseline, after 1 year, after 2 years
Inconclusive or non-malignant findings on low dose CT scans
Number and percentage
Time frame: Baseline, after 1 year, after 2 years
FEV1
Measured in liters by a lung function test
Time frame: Baseline
FVC
Measured in liters by a lung function test
Time frame: Baseline
Treatment diagnose - cancer
number and percentage of treatments by action diagnosis related to cancer
Time frame: 36 months (complete study period)
Hospitalization time
Hospitalization time related to lung cancer diagnosis measures in days
Time frame: 36 months (complete study period)
Treatment diagnose - any other disease (found on low dose CT scans)
number and percentage of treatment diagnosis related to findings of other diseases (by action diagnosis)
Time frame: 36 months (complete study period)
Referral to follow-up procedures
Number of referrals
Time frame: 36 months Entire study period
Self reported health and quality of life assessed by the EQ-5D-5L questionnair
level of percieved problems are coded from level 1 to 5 in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression"
Time frame: Baseline and after 2 years
Self-reported smoking status
Yes/no/former smoker
Time frame: Baseline, after 1 year, after 2 years
All-cause-mortality
Number of deaths in both groups (intervention/no intervention)
Time frame: 36 months (the entire study period)
Gender
Male/female
Time frame: Baseline
Weight
Kilogram
Time frame: Baseline
Height
Centimeters
Time frame: Baseline
Smoking history
according to the PLCOm2012 risk model
Time frame: baseline
Total time consumption of extra work at involved departments: department of lung diseases, department of radiology and department og pulmonary diseases
hours
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 28 months is below that.
Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.